Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes
Journal of Surgical Oncology · 2023-09 · 128 (4) · 595-603
DOI: 10.1002/jso.27301 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Surgical Oncology, online erschienen am 30.05.2023. Verfasst von Melina Deban und 14 weiteren Autor:innen. Beteiligte Einrichtung: Tom Baker Cancer Center, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Hyperthermia, Induced, Mesothelioma, Malignant, Mesothelioma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is the standard‐of‐care for patients with isolated PM. Due to a paucity of prospective data there are several different HIPEC protocols. The aims of this study are to describe the CRS and HIPEC protocols for PM and patient outcomes across Canada.
Methods
A multicenter retrospective study was performed on patients diagnosed and treated for PM with CRS and HIPEC in four major peritoneal disease centers in Canada between 2000 and 2021. Data on patient characteristics, treatment patterns, postoperative morbidity, recurrence, and survival were collected.
Results
A total of 72 patients were identified. Mean age was 52 years (17–75) and 37.5% were male. Epithelioid (70.1%) and multicystic (13%) mesothelioma were the most common subtypes. Twenty‐one patients (30%) were treated with neoadjuvant chemotherapy. CRS and HIPEC was performed in 64 patients (91.4%). Of these, the mean PCI was 22 (2–39) and cisplatin+doxorubicin was the most common HIPEC regimen ( n = 33, 51.6%). A semi‐closed coliseum technique was used in 68.8% of HIPECs and the mean duration of surgery was 486 min (90–1052). Clavien‐Dindo III or IV complications occurred in 12 patients (16.9%). With a median follow‐up of 24 months (0.2–104.4), we found a 5‐year overall survival of 61% and a 5‐year recurrence‐free survival of 35%.
Conclusion
CRS and HIPEC is a safe and effective treatment modality for well‐selected patients with PM, with some achieving prolonged survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Tom Baker Cancer Center, Calgary, Alberta, Canada.
- Vancouver General Hospital, Vancouver, British Columbia, Canada.
- QE II Health Sciences Center, Halifax, Nova Scotia, Canada.
- Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
Zitieren
APA
Deban, M., Taqi, K., Knapp, G. C., Soucisse, M., Curry, M., Sidéris, L., Dubé, P., Khaldi, M. A., Jedrzejko, N., Porter, G., Giacomantonio, C., Hamilton, T., MacNeill, A., Mack, L., & Bouchard-Fortier, A. (2023). Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes. Journal of Surgical Oncology, 128(4), 595-603. https://doi.org/10.1002/jso.27301
Vancouver
Deban M, Taqi K, Knapp GC, Soucisse M, Curry M, Sidéris L, et al. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes. Journal of Surgical Oncology. 2023;128(4):595-603. doi:10.1002/jso.27301
BibTeX
@article{Deban2023,
author = {Deban, Melina and Taqi, Kadhim and Knapp, Gregory C and Soucisse, Mikael and Curry, Matt and Sidéris, Lucas and Dubé, Pierre and Khaldi, Maher Al and Jedrzejko, Nicole and Porter, Geoff and Giacomantonio, Carman and Hamilton, Trevor and MacNeill, Andrea and Mack, Lloyd and Bouchard-Fortier, Antoine},
title = {Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes},
journal = {Journal of Surgical Oncology},
year = {2023},
volume = {128},
number = {4},
pages = {595--603},
doi = {10.1002/jso.27301}
}
EUVIMED